CpG岛甲基化表型结直肠癌治疗的进展
Advances in CpG Island Methylator Phenotype Colorectal Cancer Therapies.
作者信息
Zhang Xiaofei, Zhang Wenjun, Cao Pingan
机构信息
Department of Medical Oncology, Dalian University Affiliated Xinhua Hospital, Dalian, China.
Department of Colorectal Surgery, Dalian University Affiliated Xinhua Hospital, Dalian, China.
出版信息
Front Oncol. 2021 Feb 26;11:629390. doi: 10.3389/fonc.2021.629390. eCollection 2021.
Abstract
With the aging of the population, the incidence of colorectal cancer in China is increasing. One of the epigenetic alterations: CpG island methylator phenotype (CIMP) plays an important role in the incidence of colorectal cancer. Recent studies have shown that CIMP is closely related to some specific clinicopathological phenotypes and multiple molecular phenotypes in colorectal cancer. In this paper, the newest progress of CIMP colorectal cancer in chemotherapeutic drugs, targeted agents and small molecular methylation inhibitors are going to be introduced. We hope to provide potential clinical treatment strategies for personalized and precise treatment of colorectal cancer patients.
摘要
随着人口老龄化，中国结直肠癌的发病率正在上升。表观遗传改变之一：CpG岛甲基化表型（CIMP）在结直肠癌的发病中起重要作用。最近的研究表明，CIMP与结直肠癌的一些特定临床病理表型和多种分子表型密切相关。本文将介绍CIMP结直肠癌在化疗药物、靶向药物和小分子甲基化抑制剂方面的最新进展。我们希望为结直肠癌患者的个性化精准治疗提供潜在的临床治疗策略。
相似文献
1
Advances in CpG Island Methylator Phenotype Colorectal Cancer Therapies.
Front Oncol. 2021 Feb 26;11:629390. doi: 10.3389/fonc.2021.629390. eCollection 2021.
2
Are clinicopathological features of colorectal cancers with methylation in half of CpG island methylator phenotype panel markers different from those of CpG island methylator phenotype-high colorectal cancers?
Hum Pathol. 2016 Jan;47(1):85-94. doi: 10.1016/j.humpath.2015.09.008. Epub 2015 Sep 25.
3
Epigenetic alterations in colorectal cancer: the CpG island methylator phenotype.
Histol Histopathol. 2013 May;28(5):585-95. doi: 10.14670/HH-28.585. Epub 2013 Jan 23.
4
CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer.
Int J Clin Oncol. 2016 Dec;21(6):1091-1101. doi: 10.1007/s10147-016-1017-6. Epub 2016 Jul 19.
5
The CpG island methylator phenotype correlates with long-range epigenetic silencing in colorectal cancer.
Mol Cancer Res. 2008 Apr;6(4):585-91. doi: 10.1158/1541-7786.MCR-07-2158.
6
Isocitrate dehydrogenase 1 R132C mutation occurs exclusively in microsatellite stable colorectal cancers with the CpG island methylator phenotype.
Epigenetics. 2014 Nov;9(11):1454-60. doi: 10.4161/15592294.2014.971624.
7
Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer.
Gut. 2007 Nov;56(11):1564-71. doi: 10.1136/gut.2007.119750. Epub 2007 Mar 5.
8
Biological significance of the CpG island methylator phenotype.
Biochem Biophys Res Commun. 2014 Dec 5;455(1-2):35-42. doi: 10.1016/j.bbrc.2014.07.007. Epub 2014 Jul 10.
9
Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review.
Clin Epigenetics. 2016 Mar 2;8:25. doi: 10.1186/s13148-016-0191-8. eCollection 2016.
10
18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high.
BMC Cancer. 2007 May 2;7:72. doi: 10.1186/1471-2407-7-72.
引用本文的文献
1
Research progress on the diagnostic value of fecal calprotectin in colorectal tumors.
Front Med (Lausanne). 2025 Jul 9;12:1626197. doi: 10.3389/fmed.2025.1626197. eCollection 2025.
2
Insight into the role of DNA methylation in prognosis and treatment response prediction of gastrointestinal cancers.
Epigenomics. 2025 May;17(7):475-488. doi: 10.1080/17501911.2025.2476380. Epub 2025 Mar 14.
3
Redefining Therapeutic Approaches in Colorectal Cancer: Targeting Molecular Pathways and Overcoming Resistance.
Int J Mol Sci. 2024 Nov 21;25(23):12507. doi: 10.3390/ijms252312507.
4
Early colorectal cancer diagnosis: A novel methylated stool DNA model enhanced the diagnostic efficiency.
United European Gastroenterol J. 2025 Apr;13(3):402-415. doi: 10.1002/ueg2.12696. Epub 2024 Nov 2.
5
Deep learning-based histological predictions of chromosomal instability in colorectal cancer.
Am J Cancer Res. 2024 Sep 15;14(9):4495-4505. doi: 10.62347/JYND6488. eCollection 2024.
6
Unmasking early colorectal cancer clues: in silico and in vitro investigation of downregulated IGF2, SOCS1, MLH1, and CACNA1G in SSA polyps.
Mol Biol Rep. 2024 Jun 14;51(1):764. doi: 10.1007/s11033-024-09683-3.
7
Hypermethylated Colorectal Cancer Tumours Present a Myc-Driven Hypermetabolism with a One-Carbon Signature Associated with Worsen Prognosis.
Biomedicines. 2024 Mar 6;12(3):590. doi: 10.3390/biomedicines12030590.
8
Current Status of Cancer Genomics and Imaging Phenotypes: What Radiologists Need to Know.
Radiol Imaging Cancer. 2023 Nov;5(6):e220153. doi: 10.1148/rycan.220153.
9
A Multi-Omics Overview of Colorectal Cancer to Address Mechanisms of Disease, Metastasis, Patient Disparities and Outcomes.
Cancers (Basel). 2023 May 26;15(11):2934. doi: 10.3390/cancers15112934.
10
Transcriptomes of the tumor-adjacent normal tissues are more informative than tumors in predicting recurrence in colorectal cancer patients.
J Transl Med. 2023 Mar 21;21(1):209. doi: 10.1186/s12967-023-04053-2.
本文引用的文献
1
Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer.
Clin Colorectal Cancer. 2021 Jun;20(2):137-147.e1. doi: 10.1016/j.clcc.2020.09.007. Epub 2020 Oct 12.
2
Targeting the epigenetic regulation of antitumour immunity.
Nat Rev Drug Discov. 2020 Nov;19(11):776-800. doi: 10.1038/s41573-020-0077-5. Epub 2020 Sep 14.
3
Cancer registration in China and its role in cancer prevention and control.
Lancet Oncol. 2020 Jul;21(7):e342-e349. doi: 10.1016/S1470-2045(20)30073-5.
4
Primary Tumor Location as a Prognostic and Predictive Marker in Metastatic Colorectal Cancer (mCRC).
Front Oncol. 2020 Jun 16;10:964. doi: 10.3389/fonc.2020.00964. eCollection 2020.
5
Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer.
BMC Cancer. 2019 Oct 17;19(1):964. doi: 10.1186/s12885-019-6144-9.
6
Epidrugs: targeting epigenetic marks in cancer treatment.
Epigenetics. 2019 Dec;14(12):1164-1176. doi: 10.1080/15592294.2019.1640546. Epub 2019 Jul 13.
7
Phase I clinical trial of decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases.
ESMO Open. 2019 Mar 5;4(2):e000464. doi: 10.1136/esmoopen-2018-000464. eCollection 2019.
8
Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy.
PLoS One. 2018 Sep 6;13(9):e0203051. doi: 10.1371/journal.pone.0203051. eCollection 2018.
9
DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer.
Clin Epigenetics. 2018 Aug 6;10(1):104. doi: 10.1186/s13148-018-0539-3.
10
Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.
Clin Cancer Res. 2018 Oct 1;24(19):4745-4753. doi: 10.1158/1078-0432.CCR-18-0866. Epub 2018 Jun 19.
Zotero 插件